METHODS: A total of 78 patients(78 eyes)who were diagnosed with neovascular glaucoma and underwent intravitreal injection of ranibizumab drugs in our hospital from June 2015 to June 2018 were selected. Sixty patients with complete follow-up data were randomly divided in the experimental group(A), 30 patients(30 eyes)underwent EX-PRESS glaucoma drainage device implantation. Postoperative complications were observed early, visual acuity and intraocular pressure were observed at 1wk, 1mo, 3mo, 6mo and 1a, and the success rate of the operation was evaluated at 6mo and 1a.

RESULTS:After 1wk, 1, 3mo, 25 eyes, 25 eyes and 23 eyes with BCVA <0.1 in the experimental group, the average intraocular pressure was 16.76±3.21mmHg, 15.63±2.70mmHg and 16.69±3.29mmHg, the control group was 26 eyes, 26 eyes and 25 eyes, the average IOP was 17.31±2.96mmHg, 14.44±2.53mmHg and 16.56±4.14mmHg(all P>0.05); 6mo after operation, 16 eyes and 16 eyes in the 1a test group with BCVA <0.1 were the average IOP 15.49±3.19mmHg, 18.52±4.03mmHg, the control group was 25 eyes and 25 eyes, the average intraocular pressure was 21.96±2.90mmHg, 28.90±4.33mmHg(all P<0.05); the experimental group had low intraocular pressure, shallow The number of cases of anterior chamber, anterior chamber hemorrhage, inflammation, choroidal detachment were 0 eyes, 1 eyes, 2 eyes, 1 eyes, 0 eyes, while the control group were 6 eyes, 6 eyes, 5 eyes, 4 eyes, 2 eyes(P<0.05); 6mo after operation in the experimental group, the success rate of 1a operation was 83% and 80%, while that in the control group was 60% and 53%, respectively(P<0.05).

CONCLUSION: EX-PRESS glaucoma drainage implantation combined with ranibizumab drug treatment in the vitreous cavity can effectively reduce the intraocular pressure in patients with neovascular glaucoma and has the advantages of small surgical incision, simple operation, safety, fewer postoperative complications, and high success rate of surgery.